Papiller Tiroid Mikrokarsinomunda Mikrodalga Ablasyon Tedavisinin Etkinliği ve Prognozunun Kontrastlı Ultrason ile Genetik ve Moleküler Tanı Kombinasyonuyla Değerlendirilmesi: İleriye Dönük Gözlemsel Bir Çalışma

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

* Aged 18-70 years, gender not specified;
* Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood);
* Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery;
* Patients voluntarily choose to undergo microwave ablation therapy or surgical resection.

Exclusion Criteria:

* Tumor located in the isthmus of the thyroid;
* Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid/insular subtype, oncocytic subtype);
* Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months);
* Pregnant women, lactating women;
* Patients with severe coagulation disorders;
* Patients with contralateral vocal cord dysfunction;
* Patients with contraindications to ultrasound contrast agents;
* Other conditions deemed ineligible for enrollment by the investigator.